What is Dermala?
Dermala operates at the intersection of biotechnology and consumer wellness, offering a highly personalized approach to acne management. By focusing on the human microbiome, the company develops targeted solutions including supplements, cleansers, and moisturizers designed to restore balance to the skin's ecosystem. Unlike conventional over-the-counter remedies, Dermala utilizes individual skin assessments to curate customized treatment kits, ensuring that users receive a tailored regimen that addresses the root causes of their skin concerns. This data-centric model allows the company to maintain a high degree of efficacy and customer retention, positioning it as a leader in the personalized dermatology sector.
How much funding has Dermala raised?
Dermala has raised a total of $6.7M across 1 funding round:
Series A
$6.7M
Series A (2020): $6.7M with participation from True Wealth Ventures, Seventure Partners, Cove Fund II, and JJDC
Key Investors in Dermala
True Wealth Ventures
True Wealth Ventures is a venture capital fund designed to invest in women-led companies that will design, develop, go to market and scale consumer health and sustainable products and technologies to more efficiently address and solve the next generation of challenges.
Seventure Partners
Seventure Partners is an active partner of innovative companies in the fields of digital technologies and life sciences, investing in a broad range of sectors including health, nutrition, and sustainable blue economy initiatives.
JJDC
JJDC is the strategic venture capital arm of Johnson & Johnson, focusing on investing in innovative companies that align with the broader healthcare and life sciences mission of the parent organization.
What's next for Dermala?
With the recent capital injection, Dermala is poised to accelerate its growth trajectory by enhancing its data analytics capabilities and expanding its product distribution channels. The strategic focus will likely shift toward deepening its research into microbiome-based therapies, potentially broadening its portfolio to address a wider array of skin conditions beyond acne. As the company scales, it will leverage its existing partnerships to refine its supply chain and improve the accessibility of its personalized kits. The current funding context suggests a transition toward market dominance, where Dermala will aim to solidify its brand equity and establish itself as the premier authority in microbiome-focused skin health solutions.
See full Dermala company page
